drugset / Trial / NCT02716129

The Effect of Adding Nalbuphine to Intrathecal Morphine on Analgesic Efficacy and Side Effects After Cesarean Section

NCT02716129

Phase 2 Completed 80 enrolled Abdelrady S Ibrahim, MD
RandomizedParallel-groupDouble-blindPrevention

Summary

The primary endpoint of this study is to investigate the effect of adding nalbuphine to intrathecal morphine on quality of postoperative analgesia and Morphine related side effects post- cesarean delivery.

Timeline

Start
2016-07
Primary completion
2017-10
Completion
2017-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Morphine Other / unclassified 0.2 mg Intrathecal
Comparator Morphine Other / unclassified 0.5 mg Intrathecal
Comparator Nalbuphine Small molecule 0.2 mg
Comparator Bupivacaine Other / unclassified 10 mg Intrathecal

Indications

No indication recorded.